Pacific Biosciences of California, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Pacific Biosciences of California, Inc. (PACB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $9.26 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Pacific Biosciences of California, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $9.26M, a 22.13% decline year-over-year.
- Pacific Biosciences of California, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $4.46M, a 51.54% decline year-over-year.
- Pacific Biosciences of California, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $9.59M, a 40.20% decline year-over-year.
- Pacific Biosciences of California, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $10.98M, a 39.84% decline year-over-year.
- Pacific Biosciences of California, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $41.67M, a 41.34% decline from fiscal 2024.
- Pacific Biosciences of California, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $71.04M, a 1.50% decline from fiscal 2023.
- Pacific Biosciences of California, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $72.12M, a 8.26% decline from fiscal 2022.
- Pacific Biosciences of California, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $78.61M, a 7.17% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.26M 10-Q · filed 2026-08-06 | $13.72M 10-Q · filed 2026-08-06 | $23.31M derived: sum of 3 quarters · filed 2026-08-06 | $34.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.46M 10-Q · filed 2026-05-08 | $14.05M derived: sum of 2 quarters · filed 2026-05-08 | $25.03M derived: sum of 3 quarters · filed 2026-05-08 | $36.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $9.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $20.57M derived: sum of 2 quarters · filed 2026-02-25 | $32.47M derived: sum of 3 quarters · filed 2026-08-06 | $41.67M 10-K · filed 2026-02-25 |
| 2025-09-30 | $10.98M 10-Q · filed 2025-11-06 | $22.88M derived: sum of 2 quarters · filed 2026-08-06 | $32.08M 10-Q · filed 2025-11-06 | $48.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $11.89M 10-Q · filed 2026-08-06 | $21.10M 10-Q · filed 2026-08-06 | $37.13M derived: sum of 3 quarters · filed 2026-08-06 | $55.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $9.20M 10-Q · filed 2026-05-08 | $25.23M derived: sum of 2 quarters · filed 2026-05-08 | $43.49M derived: sum of 3 quarters · filed 2026-05-08 | $60.71M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $16.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $34.29M derived: sum of 2 quarters · filed 2026-02-25 | $51.51M derived: sum of 3 quarters · filed 2026-02-25 | $71.04M 10-K · filed 2026-02-25 |
| 2024-09-30 | $18.26M 10-Q · filed 2025-11-06 | $35.48M derived: sum of 2 quarters · filed 2025-11-06 | $55.00M 10-Q · filed 2025-11-06 | $71.59M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $17.22M 10-Q · filed 2025-08-07 | $36.74M 10-Q · filed 2025-08-07 | $53.33M derived: sum of 3 quarters · filed 2026-02-25 | $73.02M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $19.52M 10-Q · filed 2025-05-12 | $36.11M derived: sum of 2 quarters · filed 2026-02-25 | $55.80M derived: sum of 3 quarters · filed 2026-02-25 | $73.69M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $16.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $36.27M derived: sum of 2 quarters · filed 2026-02-25 | $54.17M derived: sum of 3 quarters · filed 2026-02-25 | $72.12M 10-K · filed 2026-02-25 |
| 2023-09-30 | $19.69M 10-Q · filed 2024-11-12 | $37.58M derived: sum of 2 quarters · filed 2024-11-12 | $55.53M 10-Q · filed 2024-11-12 | $73.49M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $17.89M 10-Q · filed 2024-08-09 | $35.84M 10-Q · filed 2024-08-09 | $53.80M derived: sum of 3 quarters · filed 2025-03-17 | $72.73M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $17.95M 10-Q · filed 2024-05-09 | $35.91M derived: sum of 2 quarters · filed 2025-03-17 | $54.84M derived: sum of 3 quarters · filed 2025-03-17 | $74.07M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $17.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $36.89M derived: sum of 2 quarters · filed 2025-03-17 | $56.12M derived: sum of 3 quarters · filed 2025-03-17 | $78.61M 10-K · filed 2025-03-17 |
| 2022-09-30 | $18.94M 10-Q · filed 2023-11-03 | $38.16M derived: sum of 2 quarters · filed 2023-11-03 | $60.66M 10-Q · filed 2023-11-03 | $79.60M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $19.23M 10-Q · filed 2023-08-04 | $41.72M 10-Q · filed 2023-08-04 | $60.66M derived: sum of 3 quarters · filed 2024-02-28 | $89.11M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $22.50M 10-Q · filed 2023-05-04 | $41.43M derived: sum of 2 quarters · filed 2024-02-28 | $69.88M derived: sum of 3 quarters · filed 2024-02-28 | $85.69M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $18.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $47.38M derived: sum of 2 quarters · filed 2024-02-28 | $63.19M derived: sum of 3 quarters · filed 2024-02-28 | $73.36M 10-K · filed 2024-02-28 |
| 2021-09-30 | $28.45M 10-Q · filed 2022-11-08 | $44.25M derived: sum of 2 quarters · filed 2022-11-08 | $54.42M 10-Q · filed 2022-11-08 | $59.69M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $15.80M 10-Q · filed 2022-08-08 | $25.97M 10-Q · filed 2022-08-08 | $31.25M derived: sum of 3 quarters · filed 2023-02-28 | $36.24M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $10.16M 10-Q · filed 2022-05-06 | $15.44M derived: sum of 2 quarters · filed 2023-02-28 | $20.43M derived: sum of 3 quarters · filed 2023-02-28 | $23.67M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $10.27M derived: sum of 2 quarters · filed 2023-02-28 | $13.50M derived: sum of 3 quarters · filed 2023-02-28 | $17.53M 10-K · filed 2023-02-28 |
| 2020-09-30 | $4.99M 10-Q · filed 2021-11-05 | $8.23M derived: sum of 2 quarters · filed 2021-11-05 | $12.26M 10-Q · filed 2021-11-05 | $16.13M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $3.23M 10-Q · filed 2021-08-06 | $7.27M 10-Q · filed 2021-08-06 | $11.13M derived: sum of 3 quarters · filed 2022-02-28 | $15.20M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $4.03M 10-Q · filed 2021-05-06 | $7.90M derived: sum of 2 quarters · filed 2022-02-28 | $11.96M derived: sum of 3 quarters · filed 2022-02-28 | $16.05M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $3.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $7.93M derived: sum of 2 quarters · filed 2022-02-28 | $12.02M derived: sum of 3 quarters · filed 2022-02-28 | $16.40M 10-K · filed 2022-02-28 |
| 2019-09-30 | $4.06M 10-Q · filed 2020-11-03 | $8.15M derived: sum of 2 quarters · filed 2020-11-03 | $12.53M 10-Q · filed 2020-11-03 | $20.05M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $4.09M 10-Q · filed 2020-08-06 | $8.47M 10-Q · filed 2020-08-06 | $15.99M derived: sum of 3 quarters · filed 2021-02-26 | $21.12M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $4.38M 10-Q · filed 2020-05-08 | $11.90M derived: sum of 2 quarters · filed 2021-02-26 | $17.03M derived: sum of 3 quarters · filed 2021-02-26 | $22.25M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $7.52M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $12.65M derived: sum of 2 quarters · filed 2021-02-26 | $17.87M derived: sum of 3 quarters · filed 2021-02-26 | $23.15M 10-K · filed 2021-02-26 |
| 2018-09-30 | $5.13M 10-Q · filed 2019-11-07 | $10.35M derived: sum of 2 quarters · filed 2019-11-07 | $15.63M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $5.22M 10-Q · filed 2019-08-06 | $10.51M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $5.28M 10-Q · filed 2019-05-03 | |||
| 2017-12-31 | $20.35M 10-K · filed 2020-02-28 | |||
| 2016-12-31 | $19.56M 10-K · filed 2019-02-26 | |||
| 2015-12-31 | $13.84M 10-K · filed 2018-02-26 | |||
| 2014-12-31 | $9.94M 10-K · filed 2017-03-06 | |||
| 2013-12-31 | $9.90M 10-K · filed 2016-03-11 | |||
| 2011-12-31 | $780.00K 10-K · filed 2014-03-14 | |||
| 2010-12-31 | $428.00K 10-K · filed 2013-03-15 | |||
| 2009-12-31 | $79.00K 10-K · filed 2012-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |